Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MOLECULAR DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MOLECULAR DIAGNOSTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNOLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES
17.1 OVERVIEW
17.2 PRODUCT
17.2.1 INSTRUMENTS
17.2.1.1. BY TYPE
17.2.1.1.1. FULLY AUTOMATED
17.2.1.1.2. SEMI-AUTOMATED
17.2.1.1.3. MANUAL
17.2.1.2. BY MODALITY
17.2.1.2.1. PORTABLE
17.2.1.2.2. STANDALONE
17.2.1.2.3. BENCHTOP
17.2.2 REAGENTS AND KITS
17.2.2.1. KITS
17.2.2.1.1. DNA EXTRACTION AND PURIFICATION KITS
17.2.2.1.1.1 PLASMID MINIPREP AND MAXIPREP KITS
17.2.2.1.1.2 PLASMID PURIFICATION KITS
17.2.2.1.1.3 PCR PURIFICATION KITS
17.2.2.1.1.4 GENOMIC DNA PURIFICATION KITS
17.2.2.1.1.5 OTHERS
17.2.2.1.2. RNAI AND RNA REAGENTS
17.2.2.1.3. NUCLEIC ACID PURIFICATION KITS
17.2.2.1.4. NUCLEIC ACID SYNTHESIS KITS, BUFFERS & REAGENTS
17.2.2.1.5. HPV KITS
17.2.2.1.6. TB KITS
17.2.2.1.7. DEPLETION KITS
17.2.2.1.8. OTHERS
17.2.2.2. QC SETS AND PANELS
17.2.2.2.1. CONTROL PANEL
17.2.2.2.1.1 MULTIPLEX VAGINAL CONTROL PANEL
17.2.2.2.1.2 HUMAN PAPILLOMAVIRUS (HPV) CONTROL PANEL
17.2.2.2.1.3 CANDIDA VAGINITIS/TRICHOMONAS VAGINALIS (CV/TV) CONTROL PANEL
17.2.2.2.1.4 CT/NG CONTROL PANEL
17.2.2.2.1.5 BACTERIAL VAGINOSIS (BV) CONTROL PANEL
17.2.2.2.1.6 CELLULARITY CONTROL
17.2.2.2.1.7 RESPIRATORY CONTROL PANEL
17.2.2.2.1.8 FLU/RSV/SARS-COV-2 CONTROL PANEL
17.2.2.2.1.8.1. NXG CONTROL PANEL
17.2.2.2.1.8.2. COMPLETE CONTROL PANEL
17.2.2.2.1.8.3. OTHERS
17.2.2.2.1.9 MPN PANEL
17.2.2.2.1.10 AML PANEL
17.2.2.2.1.11 QC PANEL
17.2.2.2.1.12 ALL PANEL
17.2.2.2.1.13 VERIFICATION PANEL
17.2.2.2.1.14 OTHERS
17.2.2.3. MUTATIONS DETECTION KIT
17.2.2.3.1. KRAS PCR KIT
17.2.2.3.2. EGFR KIT
17.2.2.3.3. BRAF MUTATION KIT
17.2.2.3.4. AML1-ETO KIT
17.2.2.3.5. NRAS MUTATION KIT
17.2.2.3.6. CALR KIT
17.2.2.3.7. FLT3 MUTATION DETECTION
17.2.2.3.8. C-KIT MUTATION DETECTION KIT
17.2.2.3.9. MGMT METHYLATION DETECTION KIT
17.2.2.3.10. CBFB-MYH11 KIT
17.2.2.3.11. GENE FUSIONS DETECTION KIT
17.2.2.3.12. OTHER KITS AND ASSAYS
17.2.2.4. ENZYMES
17.2.2.4.1. POLYMERASES
17.2.2.4.2. LIGASES
17.2.2.4.3. RESTRICTION ENDONUCLEASES
17.2.2.4.4. REVERSE TRANSCRIPTASES
17.2.2.4.5. PHOSPHATASES
17.2.2.4.6. PROTEASES AND PROTEINASES
17.2.2.4.7. DNA LADDERS
17.2.2.4.8. OTHER ENZYMES
17.2.2.5. BUFFERS
17.2.2.6. PRIMERS
17.2.2.7. OTHERS
17.3 SOFTWARE AND SERVICES
17.3.1 SERVICES
17.3.1.1. INSTRUMENT REPAIR SERVICES
17.3.1.1.1. ON-SITE REPAIR SERVICES
17.3.1.1.2. OFF-SITE REPAIR SERVICES
17.3.1.2. TRAINING SERVICES
17.3.1.2.1. PCR BASED MOLECULAR DIAGNOSTICS
17.3.1.2.2. IMMUNOHISTOCHEMISTRY (IHC)
17.3.1.2.3. VIRAL LOAD TESTING
17.3.1.2.4. INTERPHASE CHROMOSOME PROFILING (ICP)
17.3.1.2.5. OTHERS
17.3.1.3. COMPLIANCE SERVICES
17.3.1.3.1. IQ/OQ & PM/OQ SERVICES
17.3.1.3.2. INSTALLATION SERVICES
17.3.1.3.3. VALIDATION SERVICES
17.3.1.3.4. OTHER SERVICES
17.3.1.4. SCALABLE AUTOMATION SERVICES
17.3.1.4.1. AUTOMATION FOR HIGH-CONTENT SCREENING (HCS)
17.3.1.4.2. AUTOMATION FOR HIGH-THROUGHPUT PLATE-BASED ASSAYS
17.3.1.4.3. AUTOMATION FOR HIGH-THROUGHPUT CLONE SCREENING
17.3.1.5. CALIBRATION SERVICES
17.3.1.6. MAINTENANCE SERVICES
17.3.1.7. INSTRUMENT RELOCATION SERVICES
17.3.1.7.1. PLATE RECERTIFICATION
17.3.1.7.2. FACTORY APPROVED PARTS
17.3.1.7.3. INSTRUMENT PERFORMANCE EVALUATION
17.3.1.7.4. OTHER SERVICES
17.3.1.8. HARDWARE CUSTOMIZATION
17.3.1.9. PERFORMANCE ASSURANCE SERVICES
17.3.1.10. DESIGN AND DEVELOPMENT SERVICES
17.3.1.11. SUPPLY CHAIN SOLUTIONS
17.3.1.12. CLINICAL RESEARCH SERVICES
17.3.1.13. OTHER SERVICES
17.3.2 SOFTWARE
17.3.2.1. BY TYPE
17.3.2.1.1. INTEGRATED
17.3.2.1.2. STANDALONE
17.3.2.2. BY DEPLOYMENT
17.3.2.2.1. CLOUD BASES
17.3.2.2.2. ON-PREMISES
17.3.2.2.3. HYBRID
18 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
18.1 OVERVIEW
18.2 POLYMERASE CHAIN REACTION (PCR)
18.2.1 BY TYPE
18.2.1.1. REAL-TIME PCR
18.2.1.2. DIGITAL PCR
18.2.1.3. REVERSE TRANSCRIPTASE PCR
18.2.1.4. QUANTITATIVE FLUORESCENT PCR
18.2.1.5. COLD PCR
18.2.1.6. OTHERS
18.2.2 BY PRODUCT AND SERVICES
18.2.2.1. PRODUCT
18.2.2.2. SERVICES AND SOFTWARE
18.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
18.3.1 BY PRODUCT AND SERVICES
18.3.1.1. PRODUCT
18.3.1.2. SERVICES AND SOFTWARE
18.4 NEXT GENERATION SEQUENCING (NGS)
18.4.1 BY PRODUCT AND SERVICES
18.4.1.1. PRODUCT
18.4.1.2. SERVICES AND SOFTWARE
18.5 CYTOGENETICS
18.5.1 BY PRODUCT AND SERVICES
18.5.1.1. PRODUCT
18.5.1.2. SERVICES AND SOFTWARE
18.6 CAPILLARY ELECTROPHORESIS
18.6.1 BY PRODUCT AND SERVICES
18.6.1.1. PRODUCT
18.6.1.2. SERVICES AND SOFTWARE
18.7 IN SITU HYBRIDIZATION (ISH OR FISH)
18.7.1 BY PRODUCT AND SERVICES
18.7.1.1. PRODUCT
18.7.1.2. SERVICES AND SOFTWARE
18.8 MOLECULAR IMAGING
18.8.1 BY TYPE
18.8.1.1. OPTICAL IMAGING
18.8.1.2. FDG-PET
18.8.1.3. OTHERS
18.8.2 BY PRODUCT AND SERVICES
18.8.2.1. PRODUCT
18.8.2.2. SERVICES AND SOFTWARE
18.9 MASS SPECTROMETRY (MS)
18.9.1 BY PRODUCT AND SERVICES
18.9.1.1. PRODUCT
18.9.1.2. SERVICES AND SOFTWARE
18.1 CHIPS AND MICROARRAY
18.10.1 BY PRODUCT AND SERVICES
18.10.1.1. PRODUCT
18.10.1.2. SERVICES AND SOFTWARE
18.11 OTHERS
19 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 ONCOLOGY TESTING
19.2.1 ONCOLOGY, BY CANCER TYPE
19.2.1.1. BREAST CANCER
19.2.1.1.1. MARKET VALUE (USD MILLION)
19.2.1.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.1.1.3. AVERAGE TEST COST (USD)
19.2.1.2. COLORECTAL CANCER
19.2.1.2.1. MARKET VALUE (USD MILLION)
19.2.1.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.1.2.3. AVERAGE TEST COST (USD)
19.2.1.3. LUNG CANCER
19.2.1.3.1. MARKET VALUE (USD MILLION)
19.2.1.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.1.3.3. AVERAGE TEST COST (USD)
19.2.1.4. PROSTATE CANCER
19.2.1.4.1. MARKET VALUE (USD MILLION)
19.2.1.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.1.4.3. AVERAGE TEST COST (USD)
19.2.1.5. OTHERS
19.2.2 ONCOLOGY, BY TECHNOLOGY
19.2.2.1. POLYMERASE CHAIN REACTION (PCR)
19.2.2.1.1. MARKET VALUE (USD MILLION)
19.2.2.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.1.3. AVERAGE TEST COST (USD)
19.2.2.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.2.2.2.1. MARKET VALUE (USD MILLION)
19.2.2.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.2.3. AVERAGE TEST COST (USD)
19.2.2.3. NEXT GENERATION SEQUENCING (NGS)
19.2.2.3.1. MARKET VALUE (USD MILLION)
19.2.2.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.3.3. AVERAGE TEST COST (USD)
19.2.2.4. CYTOGENETICS
19.2.2.4.1. MARKET VALUE (USD MILLION)
19.2.2.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.4.3. AVERAGE TEST COST (USD)
19.2.2.5. CAPILLARY ELECTROPHORESIS
19.2.2.5.1. MARKET VALUE (USD MILLION)
19.2.2.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.5.3. AVERAGE TEST COST (USD)
19.2.2.6. IN SITU HYBRIDIZATION (ISH OR FISH)
19.2.2.6.1. MARKET VALUE (USD MILLION)
19.2.2.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.6.3. AVERAGE TEST COST (USD)
19.2.2.7. MOLECULAR IMAGING
19.2.2.7.1. MARKET VALUE (USD MILLION)
19.2.2.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.7.3. AVERAGE TEST COST (USD)
19.2.2.8. MASS SPECTROMETRY (MS)
19.2.2.8.1. MARKET VALUE (USD MILLION)
19.2.2.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.8.3. AVERAGE TEST COST (USD)
19.2.2.9. CHIPS AND MICROARRAY
19.2.2.9.1. MARKET VALUE (USD MILLION)
19.2.2.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.2.2.9.3. AVERAGE TEST COST (USD)
19.2.2.10. OTHERS
19.3 PHARMACOGENOMICS
19.3.1 POLYMERASE CHAIN REACTION (PCR)
19.3.1.1. MARKET VALUE (USD MILLION)
19.3.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.1.3. AVERAGE TEST COST (USD)
19.3.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.3.2.1. MARKET VALUE (USD MILLION)
19.3.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.2.3. AVERAGE TEST COST (USD)
19.3.3 NEXT GENERATION SEQUENCING (NGS)
19.3.3.1. MARKET VALUE (USD MILLION)
19.3.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.3.3. AVERAGE TEST COST (USD)
19.3.4 CYTOGENETICS
19.3.4.1. MARKET VALUE (USD MILLION)
19.3.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.4.3. AVERAGE TEST COST (USD)
19.3.5 CAPILLARY ELECTROPHORESIS
19.3.5.1. MARKET VALUE (USD MILLION)
19.3.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.5.3. AVERAGE TEST COST (USD)
19.3.6 IN SITU HYBRIDIZATION (ISH OR FISH)
19.3.6.1. MARKET VALUE (USD MILLION)
19.3.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.6.3. AVERAGE TEST COST (USD)
19.3.7 MOLECULAR IMAGING
19.3.7.1. MARKET VALUE (USD MILLION)
19.3.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.7.3. AVERAGE TEST COST (USD)
19.3.8 MASS SPECTROMETRY (MS)
19.3.8.1. MARKET VALUE (USD MILLION)
19.3.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.8.3. AVERAGE TEST COST (USD)
19.3.9 CHIPS AND MICROARRAY
19.3.9.1. MARKET VALUE (USD MILLION)
19.3.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.3.9.3. AVERAGE TEST COST (USD)
19.3.10 OTHERS
19.4 MICROBIOLOGY
19.4.1 POLYMERASE CHAIN REACTION (PCR)
19.4.1.1. MARKET VALUE (USD MILLION)
19.4.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.1.3. AVERAGE TEST COST (USD)
19.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.4.2.1. MARKET VALUE (USD MILLION)
19.4.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.2.3. AVERAGE TEST COST (USD)
19.4.3 NEXT GENERATION SEQUENCING (NGS)
19.4.3.1. MARKET VALUE (USD MILLION)
19.4.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.3.3. AVERAGE TEST COST (USD)
19.4.4 CYTOGENETICS
19.4.4.1. MARKET VALUE (USD MILLION)
19.4.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.4.3. AVERAGE TEST COST (USD)
19.4.5 CAPILLARY ELECTROPHORESIS
19.4.5.1. MARKET VALUE (USD MILLION)
19.4.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.5.3. AVERAGE TEST COST (USD)
19.4.6 IN SITU HYBRIDIZATION (ISH OR FISH)
19.4.6.1. MARKET VALUE (USD MILLION)
19.4.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.6.3. AVERAGE TEST COST (USD)
19.4.7 MOLECULAR IMAGING
19.4.7.1. MARKET VALUE (USD MILLION)
19.4.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.7.3. AVERAGE TEST COST (USD)
19.4.8 MASS SPECTROMETRY (MS)
19.4.8.1. MARKET VALUE (USD MILLION)
19.4.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.8.3. AVERAGE TEST COST (USD)
19.4.9 CHIPS AND MICROARRAY
19.4.9.1. MARKET VALUE (USD MILLION)
19.4.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.4.9.3. AVERAGE TEST COST (USD)
19.4.10 OTHERS
19.5 PRENATAL TESTS
19.5.1 SICKLE CELL DISEASE
19.5.1.1. MARKET VALUE (USD MILLION)
19.5.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.5.1.3. AVERAGE TEST COST (USD)
19.5.2 CYSTIC FIBROSIS
19.5.2.1. MARKET VALUE (USD MILLION)
19.5.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.5.2.3. AVERAGE TEST COST (USD)
19.5.3 TAY-SACHS DISEASE
19.5.3.1. MARKET VALUE (USD MILLION)
19.5.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.5.3.3. AVERAGE TEST COST (USD)
19.5.4 OTHERS
19.6 TISSUE TYPING TEST
19.6.1 POLYMERASE CHAIN REACTION (PCR)
19.6.1.1. MARKET VALUE (USD MILLION)
19.6.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.1.3. AVERAGE TEST COST (USD)
19.6.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.6.2.1. MARKET VALUE (USD MILLION)
19.6.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.2.3. AVERAGE TEST COST (USD)
19.6.3 NEXT GENERATION SEQUENCING (NGS)
19.6.3.1. MARKET VALUE (USD MILLION)
19.6.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.3.3. AVERAGE TEST COST (USD)
19.6.4 CYTOGENETICS
19.6.4.1. MARKET VALUE (USD MILLION)
19.6.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.4.3. AVERAGE TEST COST (USD)
19.6.5 CAPILLARY ELECTROPHORESIS
19.6.5.1. MARKET VALUE (USD MILLION)
19.6.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.5.3. AVERAGE TEST COST (USD)
19.6.6 IN SITU HYBRIDIZATION (ISH OR FISH)
19.6.6.1. MARKET VALUE (USD MILLION)
19.6.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.6.3. AVERAGE TEST COST (USD)
19.6.7 MOLECULAR IMAGING
19.6.7.1. MARKET VALUE (USD MILLION)
19.6.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.7.3. AVERAGE TEST COST (USD)
19.6.8 MASS SPECTROMETRY (MS)
19.6.8.1. MARKET VALUE (USD MILLION)
19.6.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.8.3. AVERAGE TEST COST (USD)
19.6.9 CHIPS AND MICROARRAY
19.6.9.1. MARKET VALUE (USD MILLION)
19.6.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.6.9.3. AVERAGE TEST COST (USD)
19.6.10 OTHERS
19.7 BLOOD SCREENING
19.7.1 POLYMERASE CHAIN REACTION (PCR)
19.7.1.1. MARKET VALUE (USD MILLION)
19.7.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.1.3. AVERAGE TEST COST (USD)
19.7.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.7.2.1. MARKET VALUE (USD MILLION)
19.7.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.2.3. AVERAGE TEST COST (USD)
19.7.3 NEXT GENERATION SEQUENCING (NGS)
19.7.3.1. MARKET VALUE (USD MILLION)
19.7.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.3.3. AVERAGE TEST COST (USD)
19.7.4 CYTOGENETICS
19.7.4.1. MARKET VALUE (USD MILLION)
19.7.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.4.3. AVERAGE TEST COST (USD)
19.7.5 CAPILLARY ELECTROPHORESIS
19.7.5.1. MARKET VALUE (USD MILLION)
19.7.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.5.3. AVERAGE TEST COST (USD)
19.7.6 IN SITU HYBRIDIZATION (ISH OR FISH)
19.7.6.1. MARKET VALUE (USD MILLION)
19.7.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.6.3. AVERAGE TEST COST (USD)
19.7.7 MOLECULAR IMAGING
19.7.7.1. MARKET VALUE (USD MILLION)
19.7.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.7.3. AVERAGE TEST COST (USD)
19.7.8 MASS SPECTROMETRY (MS)
19.7.8.1. MARKET VALUE (USD MILLION)
19.7.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.8.3. AVERAGE TEST COST (USD)
19.7.9 CHIPS AND MICROARRAY
19.7.9.1. MARKET VALUE (USD MILLION)
19.7.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.7.9.3. AVERAGE TEST COST (USD)
19.7.10 OTHERS
19.8 CARDIOVASCULAR DISEASES TESTING
19.8.1 POLYMERASE CHAIN REACTION (PCR)
19.8.1.1. MARKET VALUE (USD MILLION)
19.8.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.1.3. AVERAGE TEST COST (USD)
19.8.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.8.2.1. MARKET VALUE (USD MILLION)
19.8.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.2.3. AVERAGE TEST COST (USD)
19.8.3 NEXT GENERATION SEQUENCING (NGS)
19.8.3.1. MARKET VALUE (USD MILLION)
19.8.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.3.3. AVERAGE TEST COST (USD)
19.8.4 CYTOGENETICS
19.8.4.1. MARKET VALUE (USD MILLION)
19.8.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.4.3. AVERAGE TEST COST (USD)
19.8.5 CAPILLARY ELECTROPHORESIS
19.8.5.1. MARKET VALUE (USD MILLION)
19.8.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.5.3. AVERAGE TEST COST (USD)
19.8.6 IN SITU HYBRIDIZATION (ISH OR FISH)
19.8.6.1. MARKET VALUE (USD MILLION)
19.8.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.6.3. AVERAGE TEST COST (USD)
19.8.7 MOLECULAR IMAGING
19.8.7.1. MARKET VALUE (USD MILLION)
19.8.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.7.3. AVERAGE TEST COST (USD)
19.8.8 MASS SPECTROMETRY (MS)
19.8.8.1. MARKET VALUE (USD MILLION)
19.8.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.8.3. AVERAGE TEST COST (USD)
19.8.9 CHIPS AND MICROARRAY
19.8.9.1. MARKET VALUE (USD MILLION)
19.8.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.8.9.3. AVERAGE TEST COST (USD)
19.8.10 OTHERS
19.9 NEUROLOGICAL DISEASES TESTING
19.9.1 POLYMERASE CHAIN REACTION (PCR)
19.9.1.1. MARKET VALUE (USD MILLION)
19.9.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.1.3. AVERAGE TEST COST (USD)
19.9.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.9.2.1. MARKET VALUE (USD MILLION)
19.9.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.2.3. AVERAGE TEST COST (USD)
19.9.3 NEXT GENERATION SEQUENCING (NGS)
19.9.3.1. MARKET VALUE (USD MILLION)
19.9.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.3.3. AVERAGE TEST COST (USD)
19.9.4 CYTOGENETICS
19.9.4.1. MARKET VALUE (USD MILLION)
19.9.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.4.3. AVERAGE TEST COST (USD)
19.9.5 CAPILLARY ELECTROPHORESIS
19.9.5.1. MARKET VALUE (USD MILLION)
19.9.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.5.3. AVERAGE TEST COST (USD)
19.9.6 IN SITU HYBRIDIZATION (ISH OR FISH)
19.9.6.1. MARKET VALUE (USD MILLION)
19.9.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.6.3. AVERAGE TEST COST (USD)
19.9.7 MOLECULAR IMAGING
19.9.7.1. MARKET VALUE (USD MILLION)
19.9.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.7.3. AVERAGE TEST COST (USD)
19.9.8 MASS SPECTROMETRY (MS)
19.9.8.1. MARKET VALUE (USD MILLION)
19.9.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.8.3. AVERAGE TEST COST (USD)
19.9.9 CHIPS AND MICROARRAY
19.9.9.1. MARKET VALUE (USD MILLION)
19.9.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.9.9.3. AVERAGE TEST COST (USD)
19.9.10 OTHERS
19.1 INFECTIOUS DISEASES TESTING
19.10.1 BY TYPE
19.10.1.1. COVID-19
19.10.1.1.1. MARKET VALUE (USD MILLION)
19.10.1.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.1.3. AVERAGE TEST COST (USD)
19.10.1.2. HEPATITIS
19.10.1.2.1. MARKET VALUE (USD MILLION)
19.10.1.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.2.3. AVERAGE TEST COST (USD)
19.10.1.3. HIV
19.10.1.3.1. MARKET VALUE (USD MILLION)
19.10.1.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.3.3. AVERAGE TEST COST (USD)
19.10.1.4. CT/NG
19.10.1.4.1. MARKET VALUE (USD MILLION)
19.10.1.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.4.3. AVERAGE TEST COST (USD)
19.10.1.5. HAI
19.10.1.5.1. MARKET VALUE (USD MILLION)
19.10.1.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.5.3. AVERAGE TEST COST (USD)
19.10.1.6. HPV
19.10.1.6.1. MARKET VALUE (USD MILLION)
19.10.1.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.6.3. AVERAGE TEST COST (USD)
19.10.1.7. TUBERCULOSIS
19.10.1.7.1. MARKET VALUE (USD MILLION)
19.10.1.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.7.3. AVERAGE TEST COST (USD)
19.10.1.8. INFLUENZA
19.10.1.8.1. MARKET VALUE (USD MILLION)
19.10.1.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.1.8.3. AVERAGE TEST COST (USD)
19.10.1.9. VECTOR-BORNE DISEASE
19.10.1.9.1. MALERIA
19.10.1.9.1.1 MARKET VALUE (USD MILLION)
19.10.1.9.1.2 MARKET VOLUME (NUMBER OF TESTS)
19.10.1.9.1.3 AVERAGE TEST COST (USD)
19.10.1.9.2. DENGUE
19.10.1.9.2.1 MARKET VALUE (USD MILLION)
19.10.1.9.2.2 MARKET VOLUME (NUMBER OF TESTS)
19.10.1.9.2.3 AVERAGE TEST COST (USD)
19.10.1.9.3. ZIKA VIRUS
19.10.1.9.3.1 MARKET VALUE (USD MILLION)
19.10.1.9.3.2 MARKET VOLUME (NUMBER OF TESTS)
19.10.1.9.3.3 AVERAGE TEST COST (USD)
19.10.1.9.4. OTHERS
19.10.2 BY TECHNOLOGY
19.10.2.1. POLYMERASE CHAIN REACTION (PCR)
19.10.2.1.1. MARKET VALUE (USD MILLION)
19.10.2.1.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.1.3. AVERAGE TEST COST (USD)
19.10.2.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
19.10.2.2.1. MARKET VALUE (USD MILLION)
19.10.2.2.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.2.3. AVERAGE TEST COST (USD)
19.10.2.3. NEXT GENERATION SEQUENCING (NGS)
19.10.2.3.1. MARKET VALUE (USD MILLION)
19.10.2.3.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.3.3. AVERAGE TEST COST (USD)
19.10.2.4. CYTOGENETICS
19.10.2.4.1. MARKET VALUE (USD MILLION)
19.10.2.4.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.4.3. AVERAGE TEST COST (USD)
19.10.2.5. CAPILLARY ELECTROPHORESIS
19.10.2.5.1. MARKET VALUE (USD MILLION)
19.10.2.5.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.5.3. AVERAGE TEST COST (USD)
19.10.2.6. IN SITU HYBRIDIZATION (ISH OR FISH)
19.10.2.6.1. MARKET VALUE (USD MILLION)
19.10.2.6.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.6.3. AVERAGE TEST COST (USD)
19.10.2.7. MOLECULAR IMAGING
19.10.2.7.1. MARKET VALUE (USD MILLION)
19.10.2.7.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.7.3. AVERAGE TEST COST (USD)
19.10.2.8. MASS SPECTROMETRY (MS)
19.10.2.8.1. MARKET VALUE (USD MILLION)
19.10.2.8.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.8.3. AVERAGE TEST COST (USD)
19.10.2.9. CHIPS AND MICROARRAY
19.10.2.9.1. MARKET VALUE (USD MILLION)
19.10.2.9.2. MARKET VOLUME (NUMBER OF TESTS)
19.10.2.9.3. AVERAGE TEST COST (USD)
19.10.2.10. OTHERS
19.11 OTHERS
20 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TESTING SITE
20.1 OVERVIEW
20.2 LABORATORY BASED
20.3 POINT OF CARE TESTING
21 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS CORE LABORATORIES
21.3 HOSPITAL ALTERNATIVE SITES
21.3.1 CLINICS
21.3.2 REFERENCE LABORATORIES
21.3.3 DIAGNOSTIC CENTERS
21.3.4 ACADEMIC & RESEARCH INSTITUTES
21.3.5 OTHERS
21.4 DECENTRALIZED TEST SITES
21.4.1 DECENTRALIZED CLINICAL LABORATORIES
21.4.2 PHARMACIES
21.4.3 HOMECARE SETTING
21.5 OTHERS
22 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDERS
22.3 RETAIL SALES
22.3.1 ONLINE SALES
22.3.2 OFFLINES SALES
22.4 OTHERS
23 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
GLOBAL MOLECULAR DIAGNOSTICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 FRANCE
23.2.3 U.K.
23.2.4 ITALY
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 TURKEY
23.2.8 BELGIUM
23.2.9 NETHERLANDS
23.2.10 SWITZERLAND
23.2.11 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 AUSTRALIA
23.3.6 SINGAPORE
23.3.7 THAILAND
23.3.8 MALAYSIA
23.3.9 INDONESIA
23.3.10 PHILIPPINES
23.3.11 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 PERU
23.4.4 CHILE
23.4.5 COLOMBIA
23.4.6 VENEZUELA
23.4.7 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 SAUDI ARABIA
23.5.3 UAE
23.5.4 EGYPT
23.5.5 ISRAEL
23.5.6 REST OF MIDDLE EAST AND AFRICA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL SWINE AND POULTRY RESPIRATORY DISEASES TREATMENT MARKET , COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL MOLECULAR DIAGNOSTICS MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.2 MERGERS & ACQUISITIONS
25.3 NEW PRODUCT DEVELOPMENT & APPROVALS
25.4 EXPANSIONS
25.5 REGULATORY CHANGES
25.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL MOLECULAR DIAGNOSTICS MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL MOLECULAR DIAGNOSTICS MARKET, COMPANY PROFILE
27.1 ABBOTT
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 SIEMENS HEALTHCARE PRIVATE LIMITED
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 THERMO FISHER SCIENTIFIC INC.
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 BD
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 BIOMÉRIEUX SA
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 DANAHER CORPORATION
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 HOLOGIC, INC.
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 MYRIAD GENETICS, INC.
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 QIAGEN
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 AGILENT TECHNOLOGIES, INC.
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 QUIDEL CORPORATION.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 BIO-RAD LABORATORIES, INC.
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ILLUMINA, INC.
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 IMMUCOR (WERFEN, S.A.)
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 DIASORIN S.P.A
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 SD BIOSENSOR
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 F. HOFFMANN-LA ROCHE LTD
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 GENEPATH DIAGNOSTICS
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 EXACT SCIENCES CORPORATION
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 GUARDANT HEALTH
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 REVVITY INC.
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 CARIS LIFE SCIENCES.
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 RANDOX LABORATORIES LTD.
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 DAAN GENE CO., LTD.
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 JIANGSU MACRO & MICRO-TEST MED-TECH CO., LTD.
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 GENOBIO PHARMACEUTICAL CO., LTD. (ERA BIOLOGY GROUP)
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 LEPU MEDICAL TECHNOLOGY(BEIJING)CO.,LTD.
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 PROMEGA CORPORATION
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
27.29 TRIPLEX INTERNATIONAL BIOSCIENCES CO. LTD.
27.29.1 COMPANY OVERVIEW
27.29.2 REVENUE ANALYSIS
27.29.3 GEOGRAPHIC PRESENCE
27.29.4 PRODUCT PORTFOLIO
27.29.5 RECENT DEVELOPMENTS
27.3 MGMED
27.30.1 COMPANY OVERVIEW
27.30.2 REVENUE ANALYSIS
27.30.3 GEOGRAPHIC PRESENCE
27.30.4 PRODUCT PORTFOLIO
27.30.5 RECENT DEVELOPMENTS
27.31 MOLBIO DIAGNOSTICS PVT. LTD.
27.31.1 COMPANY OVERVIEW
27.31.2 REVENUE ANALYSIS
27.31.3 GEOGRAPHIC PRESENCE
27.31.4 PRODUCT PORTFOLIO
27.31.5 RECENT DEVELOPMENTS
27.32 GENOME DIAGNOSTICS PVT. LTD.
27.32.1 COMPANY OVERVIEW
27.32.2 REVENUE ANALYSIS
27.32.3 GEOGRAPHIC PRESENCE
27.32.4 PRODUCT PORTFOLIO
27.32.5 RECENT DEVELOPMENTS
27.33 VELA DIAGNOSTICS
27.33.1 COMPANY OVERVIEW
27.33.2 REVENUE ANALYSIS
27.33.3 GEOGRAPHIC PRESENCE
27.33.4 PRODUCT PORTFOLIO
27.33.5 RECENT DEVELOPMENTS
27.34 SHANGHAI CHUANGKUN BIO
27.34.1 COMPANY OVERVIEW
27.34.2 REVENUE ANALYSIS
27.34.3 GEOGRAPHIC PRESENCE
27.34.4 PRODUCT PORTFOLIO
27.34.5 RECENT DEVELOPMENTS
27.35 TRANSGEN BIOTECH CO., LTD.
27.35.1 COMPANY OVERVIEW
27.35.2 REVENUE ANALYSIS
27.35.3 GEOGRAPHIC PRESENCE
27.35.4 PRODUCT PORTFOLIO
27.35.5 RECENT DEVELOPMENTS
27.36 NANJING VAZYME BIOTECH CO.,LTD.
27.36.1 COMPANY OVERVIEW
27.36.2 REVENUE ANALYSIS
27.36.3 GEOGRAPHIC PRESENCE
27.36.4 PRODUCT PORTFOLIO
27.36.5 RECENT DEVELOPMENTS
27.37 WUXI NEST BIOTECHNOLOGY CO.,LTD
27.37.1 COMPANY OVERVIEW
27.37.2 REVENUE ANALYSIS
27.37.3 GEOGRAPHIC PRESENCE
27.37.4 PRODUCT PORTFOLIO
27.37.5 RECENT DEVELOPMENTS
27.38 HANGZHOU BIGFISH BIO-TECH CO., LTD.
27.38.1 COMPANY OVERVIEW
27.38.2 REVENUE ANALYSIS
27.38.3 GEOGRAPHIC PRESENCE
27.38.4 PRODUCT PORTFOLIO
27.38.5 RECENT DEVELOPMENTS
27.39 MAGGENOME TECHNOLOGIES PVT. LTD.
27.39.1 COMPANY OVERVIEW
27.39.2 REVENUE ANALYSIS
27.39.3 GEOGRAPHIC PRESENCE
27.39.4 PRODUCT PORTFOLIO
27.39.5 RECENT DEVELOPMENTS
27.4 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.
27.40.1 COMPANY OVERVIEW
27.40.2 REVENUE ANALYSIS
27.40.3 GEOGRAPHIC PRESENCE
27.40.4 PRODUCT PORTFOLIO
27.40.5 RECENT DEVELOPMENTS
27.41 MERIDIAN BIOSCIENCE
27.41.1 COMPANY OVERVIEW
27.41.2 REVENUE ANALYSIS
27.41.3 GEOGRAPHIC PRESENCE
27.41.4 PRODUCT PORTFOLIO
27.41.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
